What are the Factors Influencing Growth in the Human Umbilical Vein Endothelial Cells (HUVEC) Market ?

Award-winning consulting firm Fact.MR’s report on the global human umbilical vein endothelial cells (HUVEC) market forecasts a healthy growth trajectory for the 2021-2031 forecast period. According to the study, rapid advancements in biotechnology and genetic engineering are opening up new growth avenues for advanced disease treatment, particularly across areas such as oncology.

As per data published by GLOBOCAN, global cancer burden rose to 19.3 million cases, while associated fatalities increased to 10 million by 2020. Amongst all the cancers, breast cancer accounts for nearly a quarter of the total cases diagnosed every year. Hence, healthcare providers are incorporating highly advanced therapeutic approaches, thereby widening the growth prospects for human umbilical vein endothelial cells.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=6216

Manufacturers are directing bulk of their investments across key regions such as China, India, and other countries in Asia Pacific. Over the years, these countries have witnessed unprecedented expansion of their existing healthcare infrastructure. This is majorly attributed to the presence of a huge population base, necessitating delivery of advanced healthcare for various chronic and infectious diseases.

Key Takeaways from Market Study
• By type, pooled donor-derived HUVECs are expected to experience elevated sales through 2031
• Oncology to emerge as a highly promising application area for HUVEC-based treatment
• The U.S. to generate multiple revenue streams for the market, across CVD treatment, oncology, and angiogenesis
• Extensive development of biotechnology and cell culture studies driving demand across India

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=S&rep_id=6216

Competitive Landscape
Prominent HUVEC providers as profiled by Fact.MR include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc. Due to the presence of such a handful of service providers, the market appears highly consolidated.

In May 2021, Merck & Co. announced 40 abstracts, seven oral presentations and seven poster discussions from company and investigator sponsored studies and external collaborations for its oncology treatment furtherance, an initiative which will likely provide tailwinds to its HUVEC portfolio.

In January 2021, PromoCell received the EXCiPACTTM certification scheme for pharmaceutical excipients to Good Manufacturing Practice (GMP) standards, which implied that the company can provide tailor-made cell culture media and reagents based on each client’s end user requirements.
More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the human umbilical vein endothelial cells market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of type (single donors and pooled donors) and application (wound healing, angiogenesis, tissue engineering, inflammation, oncology, and others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

For in-depth competitive analysis, buy now –
https://www.factmr.com/checkout/6216

Human Umbilical Vein Endothelial Cells (HUVEC) Market - Scope of Report
A recent study by Fact.MR on the human umbilical vein endothelial cells (HUVEC) market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering human umbilical vein endothelial cells.

The study also provides the dynamics responsible for influencing the future status of the market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the HUVEC market, along with their product portfolios, enhances the reliability of this comprehensive research study.

For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=S&rep_id=6216

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.